Healthcare Venture Capital
… life, and drive efficiency in healthcare delivery -
- In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions - MENLO PARK, Calif. and GREENWICH, Conn. and BOSTON, Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP4”), with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date, will build on the …
… drive efficiency in healthcare delivery - - In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions - MENLO PARK, Calif. and GREENWICH, Conn. and BOSTON, Sept. 23, Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP4”), with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date, will build on the …
… healthcare delivery -
- In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions - MENLO PARK, Calif. and GREENWICH, Conn. and BOSTON, Sept. 23, 2020 (GLOBE NEWSWIRE) – Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP4”), with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date, will build on the …
… healthcare delivery -
- In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions - MENLO PARK, Calif. and GREENWICH, Conn. and BOSTON, Sept. 23, 2020 (GLOBE NEWSWIRE) – Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP4”), with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date, will build on the …
… efficiency in healthcare delivery - - In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions - MENLO PARK, Calif. and GREENWICH, Conn. and BOSTON, September 23, 2020– Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (LVP4), with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date, will build on the …
… healthcare delivery -
- In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions - MENLO PARK, Calif. and GREENWICH, Conn. and BOSTON, Sept. 23, 2020 (GLOBE NEWSWIRE) – Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP4”), with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date, will build on the …
Graphite Bio Launches with $45 Million Series A Financing | Business Wire | 9/16/2020
… academic pioneers in the fields of gene editing and gene therapy, and is backed by Versant Ventures and Samsara BioCapital. For more information, please visit www.graphitebio.com . About Versant Ventures Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $3.2 billion under management and …
Uber Health’s top exec departs | Becker’s Hospital Review | 9/9/2020
… 1,000 healthcare organizations to build out its healthcare transportation business. Uber Health has yet to name a replacement for Mr. Trigub, according to STAT. Mr. Trigub’s startup will be incubated by Redesign Health, a healthcare venture capital firm that has backed several health-related companies like hearing aid developer Lively and men’s direct-to-consumer startup Vault Health. Read the full report here. More articles on leadership and management …
… Johnson joined a $47 million series B funding round in Thirty Madison. The startup offers telehealth visits and online prescriptions for drugs for hair loss, migraines and acid reflux. The round was led by healthcare venture capital firm Polaris Partners. Diabetes management: Digital diabetes and chronic care company OneDrop has nabbed $40 million in a series B funding round led by pharma giant Bayer. The partnership and financing will help …
Why Johnson & Johnson is investing in this niche telehealth startup | FierceHealthcare | 8/17/2020
… York City-based Thirty Madison offers telehealth visits and online prescriptions for drugs for hair loss, migraines and acid reflux. Thirty Madison has scored $47 million in a series B funding round led by healthcare venture capital firm Polaris Partners. Webinar Against Coronavirus, Knowledge is Power For organizations with a need for affordable and convenient COVID-19 antibody testing, Truvian’s Easy Check COVID-19 IgM/IgG antibody test empowers onsite …
Women in Bio: Geeta Vemuri Blazes a Trail in Venture Capital | BioSpace | 7/29/2020
Geeta Vemuri is a trailblazer. Following her time as a Managing Partner at Baxter Ventures and Baxalta Ventures, Vemuri founded Agent Capital, a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs. With the launch of Agent Capital, Vemuri is one of four women in the biopharma sector who have founded a venture capital group. The amount of money invested in …
… asset in Canadian history and worldwide academia Read more about the community impact of this investment here. VC Private Capital Regional Impact Award for Western Canada Lumira Ventures is Canada’s leading and most active healthcare venture capital firm. Lumira invests in best-in-class North American companies developing innovative therapeutics and medical technologies whose products offer transformative improvements to patient health outcomes and provide meaningful reductions to the overall cost …
… natural degradation of cell products – to destroy cancer-causing proteins that cannot be targeted by current drug types. Monte Rosa has secured an initial $32.5m of funding from its founding investor Versant Ventures, a healthcare venture capital firm, and New Enterprise Associates. It will soon launch another round of financing to raise funds to run clinical studies of some of its leading drug candidates. Now based in Boston in the …
… natural degradation of cell products – to destroy cancer-causing proteins that cannot be targeted by current drug types. Monte Rosa has secured an initial $32.5m of funding from its founding investor Versant Ventures, a healthcare venture capital firm, and New Enterprise Associates. It will soon launch another round of financing to raise funds to run clinical studies of some of its leading drug candidates. Now based in Boston in the …
Cobalt Taps iLevel Co-founder Hank Boggio to be Chief Commercial Officer | PR Newswire | 6/9/2020
… in the first half of 2020. Clients Cobalt has signed during that period, the majority focused on portfolio monitoring, include: American Family Insurance (AmFam) , the private insurance firm with direct investing Heritage Group , the healthcare venture capital firm Hastings Equity Partners , the energy sector buyout firm Kainos Capital , the food and consumer sector-focused private equity firm Liberty Hall Capital Partners , the global aerospace and defense-focused private equity firm …
… and offer unique deal access to our investors, compelling returns should follow.” About Tidewater Equity Partners: Tidewater Equity Partners is a North Carolina investment firm focusing on small company direct investment as well as healthcare venture capital . Tidewater provides unique access to small company private equity and venture capital investments for high-net-worth individuals, family offices, and small institutional investors. For More Information on Tidewater Equity Partners : Please visit …
We will get to that on page 35… — PowerPoint templates and presentation design services | 4/1/2020
We will get to that on page 35… – Working from home means that I cannot help to overhear fragments of startups pitching to a VC (my wife is a partner in a healthcare venture capital fund). You are in a Zoom call, going through a deck with a few people from the VC, and the senior management team of the company on the line. One of the impatient investors throws …
… CEO and Co-Founder, Brent Vaughan, will be staying on in an advisory capacity to support Happel and the Cognoa team through the transition and moving into a new role with Morningside Group, a healthcare venture capital firm and Cognoa’s lead investor. “I am incredibly proud of what we have achieved at Cognoa to advance the standard of care in pediatric behavioral health” said Vaughan of his time leading Cognoa …
… CEO and Co-Founder, Brent Vaughan, will be staying on in an advisory capacity to support Happel and the Cognoa team through the transition and moving into a new role with Morningside Group, a healthcare venture capital firm and Cognoa’s lead investor. “I am incredibly proud of what we have achieved at Cognoa to advance the standard of care in pediatric behavioral health” said Vaughan of his time leading Cognoa …
… CEO and Co-Founder, Brent Vaughan, will be staying on in an advisory capacity to support Happel and the Cognoa team through the transition and moving into a new role with Morningside Group, a healthcare venture capital firm and Cognoa’s lead investor. “I am incredibly proud of what we have achieved at Cognoa to advance the standard of care in pediatric behavioral health” said Vaughan of his time leading Cognoa …
Versant Ventures Announces Successful IPO by Black Diamond Therapeutics | Business Wire | 1/30/2020
… HER2 allosteric mutants. The most advanced product candidate, BDTX-189, is expected to start a combined Phase 1/2 clinical trial in the first half of 2020. About Versant Ventures Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $3.2 billion under management and …
Inovio Welcomes Biotech Leader to its Board of Directors | PR Newswire | 1/15/2020
… Officer of Aravive, a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Previously, Mr. Shepard was an Executive Partner at Sofinnova Ventures, a healthcare venture capital firm. Before that he also served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique …
Inovio Welcomes Biotech Leader to its Board of Directors | BioSpace | 1/15/2020
… Officer of Aravive, a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Previously, Mr. Shepard was an Executive Partner at Sofinnova Ventures, a healthcare venture capital firm. Before that he also served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique …
Inovio Welcomes Biotech Leader to its Board of Directors | 1/15/2020
… Officer of Aravive, a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Previously, Mr. Shepard was an Executive Partner at Sofinnova Ventures, a healthcare venture capital firm. Before that he also served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique …
Inovio Welcomes Biotech Leader to its Board of Directors - GuruFocus.com | 1/15/2020
… Officer of Aravive, a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Previously, Mr. Shepard was an Executive Partner at Sofinnova Ventures, a healthcare venture capital firm. Before that he also served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique …
About:
Editor:
